Study Title

claritypharmaceuticals

A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer

Study Details

Description:

The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.

Contacts:

Clarity Pharmaceuticals (Clarity Clinical)

clinicaltrials@claritypharmaceuticals.com

+61 0 2 9209 4037

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided